Properties and applications of nanoparticle/microparticle conveyors with adjuvant characteristics suitable for oral vaccination

Vaccination is one of the most effective approaches in the prevention and control of disease worldwide. Oral vaccination could have wide applications if effective protection cannot be achieved through traditional (eg, parenteral) routes of vaccination. However, oral administration is hampered by the difficulties in transferring vaccines in vivo. This has led to the development of materials such as carriers with potential adjuvant effects. Considering the requirements for selecting adjuvants for oral vaccines as well as the advantages of nanoparticle/microparticle materials as immune effectors and antigen conveyors, synthetic materials could improve the efficiency of oral vaccination. In this review, nanoparticles and microparticles with adjuvant characteristics are described with regard to their potential importance for oral immunization, and some promising and successful modification strategies are summarized.

[1]  M. Brook,et al.  Oral administration of polymer-grafted starch microparticles activates gut-associated lymphocytes and primes mice for a subsequent systemic antigen challenge. , 1998, Vaccine.

[2]  O. Lyubomska,et al.  Oral vaccination: where we are? , 2007, Expert opinion on drug delivery.

[3]  P. Gao,et al.  Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  J. Kreuter,et al.  Influence of the particle size on the adjuvant effect of particulate polymeric adjuvants. , 1986, Vaccine.

[5]  P. Artursson,et al.  Characterization of polyacryl starch microparticles as carriers for proteins and drugs. , 1984, Journal of pharmaceutical sciences.

[6]  S. Michalek,et al.  Ultrastructural study of liposome uptake by M cells of rat Peyer's patch: an oral vaccine system for delivery of purified antigen. , 1990, Regional immunology.

[7]  M. Jang,et al.  Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(D,L-lactide-co-glycolide) microparticles. , 1999, Vaccine.

[8]  P. Shah,et al.  Immunomodulation of atherosclerosis with a vaccine , 2005, Nature Clinical Practice Cardiovascular Medicine.

[9]  L. Saif,et al.  Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus‐like particle (VLP) boosting with ISCOM , 2004, Clinical and experimental immunology.

[10]  Tushar K. Vyas,et al.  Nanocarriers for systemic and mucosal vaccine delivery. , 2007, Recent patents on drug delivery & formulation.

[11]  S. Hasannia,et al.  A PLGA-encapsulated chimeric protein protects against adherence and toxicity of enterotoxigenic Escherichia coli. , 2014, Microbiological research.

[12]  K. Schluns,et al.  Sublingual Vaccination Induces Mucosal and Systemic Adaptive Immunity for Protection against Lung Tumor Challenge , 2014, PloS one.

[13]  R. Rappuoli,et al.  Vaccinology at the beginning of the 21st century , 2005, Current Opinion in Immunology.

[14]  Lei Zhang,et al.  Controlled and targeted release of antigens by intelligent shell for improving applicability of oral vaccines. , 2016, Biomaterials.

[15]  J. Rudra,et al.  Peptide nanofiber-CaCO3 composite microparticles as adjuvant-free oral vaccine delivery vehicles. , 2016, Journal of materials chemistry. B.

[16]  Qiuhong Wang,et al.  Upregulation of KPNβ1 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis , 2015, Tumor Biology.

[17]  Qinjie Wu,et al.  Mannan Loaded Biodegradable and Injectable Thermosensitive PCL-PEG-PCL Hydrogel for Vaccine Delivery , 2012 .

[18]  J. Mcghee,et al.  Biodegradable microspheres as a vaccine delivery system. , 1991, Molecular immunology.

[19]  J L Pedraz,et al.  Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[20]  E. Onuigbo,et al.  Preliminary evaluation of the immunoenhancement potential of Newcastle disease vaccine formulated as a cationic liposome , 2012, Avian pathology : journal of the W.V.P.A.

[21]  Manish M Patel,et al.  Burden of Acute Gastroenteritis Hospitalizations and Emergency Department Visits in US Children That Is Potentially Preventable by Rotavirus Vaccination: A Probe Study Using the Now-Withdrawn RotaShield Vaccine , 2009, Pediatrics.

[22]  Tejraj M Aminabhavi,et al.  Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[23]  J. Donnelly,et al.  Mucosal adjuvants and delivery systems for protein‐, DNA‐ and RNA‐based vaccines , 2004, Immunology and cell biology.

[24]  A. P. Terzyk,et al.  Conscious Changes of Carbon Nanotubes Cytotoxicity by Manipulation with Selected Nanofactors , 2015, Applied Biochemistry and Biotechnology.

[25]  Huey-Chuan Cheng,et al.  Effects of tremella–alginate–liposome encapsulation on oral delivery of inactivated H5N3 vaccine , 2011, Journal of microencapsulation.

[26]  C. Y. Lee,et al.  Immunogenicity and safety of Haemophilus influenzae type b conjugate vaccine (HibTITER) and a combination vaccine of diphtheria, tetanus, pertussis and HibTITER (TETRAMUNE) in two-month-old infants. , 1998, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[27]  R. Zhuo,et al.  Hyperbranched amphiphilic polymer with folate mediated targeting property. , 2010, Colloids and surfaces. B, Biointerfaces.

[28]  Y. Barenholz,et al.  A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. , 2006, Vaccine.

[29]  Mahfoozur Rahman,et al.  Colloidal drug delivery systems in vaccine delivery. , 2013, Current drug targets.

[30]  Sanyog Jain,et al.  Oral mucosal immunization using glucomannosylated bilosomes. , 2014, Journal of biomedical nanotechnology.

[31]  J L Pedraz,et al.  Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. , 2002, Vaccine.

[32]  D. Weissman,et al.  RNA based vaccines. , 2002, DNA and cell biology.

[33]  C. Chakraborty,et al.  Nanoparticles as 'smart' pharmaceutical delivery. , 2013, Frontiers in bioscience.

[34]  G. Losonsky,et al.  Safety and Immunogenicity of Oral Inactivated Whole-CellHelicobacter pylori Vaccine with Adjuvant among Volunteers with or without Subclinical Infection , 2001, Infection and Immunity.

[35]  Todd M. Allen,et al.  Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques , 2001, Nature Medicine.

[36]  G. R. Reddy,et al.  Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virus. , 2009, Veterinary microbiology.

[37]  Chuan-Chang Chuang,et al.  Role of amphotericin B upon enhancement of protective immunity elicited by oral administration with liposome-encapsulated-Japanese encephalitis virus nonstructural protein 1 (NS1) in mice. , 2010, Microbial pathogenesis.

[38]  S. Fukuyama,et al.  A novel M cell–specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses , 2007, The Journal of experimental medicine.

[39]  N. Moiré,et al.  Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route , 2017, Medical Microbiology and Immunology.

[40]  E. Garnotel,et al.  [Dukoral, oral cholera vaccine]. , 2006, Medecine tropicale : revue du Corps de sante colonial.

[41]  I. M. Belyakov,et al.  Large intestine-targeted nanoparticle-releasing oral vaccine to control genitorectal viral infection , 2012, Nature Medicine.

[42]  E. Hundt,et al.  Tetanus Toxoid Loaded Nanoparticles from Sulfobutylated Poly(Vinyl Alcohol)-Graft-Poly(Lactide-co-Glycolide): Evaluation of Antibody Response After Oral and Nasal Application in Mice , 2001, Pharmaceutical Research.

[43]  M. Ré,et al.  Preparation and evaluation of chitosan–hydrophobic silica composite microspheres: Role of hydrophobic silica in modifying their properties , 2014 .

[44]  J. Kwang,et al.  Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. , 2010, Antiviral research.

[45]  Kapil Khatri,et al.  M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B , 2007, Journal of drug targeting.

[46]  S. Geary,et al.  Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses , 2013, Human vaccines & immunotherapeutics.

[47]  Ying Sun,et al.  Intracellular trafficking and cellular uptake mechanism of mPEG-PLGA-PLL and mPEG-PLGA-PLL-Gal nanoparticles for targeted delivery to hepatomas. , 2014, Biomaterials.

[48]  N. Mishra,et al.  PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B. , 2010, International journal of pharmaceutics.

[49]  S. Pun,et al.  Application of living free radical polymerization for nucleic acid delivery. , 2012, Accounts of chemical research.

[50]  P. Heegaard,et al.  Dendrimers in drug research. , 2004, Chemical Society reviews.

[51]  H. Allcock,et al.  Ionically cross-linkable polyphosphazene: poly(bis(carboxylatophenoxy) phosphazene) and its hydrogels and membranes , 1989 .

[52]  Tao Xi,et al.  Immunogenicity characterization of the multi-epitope vaccine CTB-UE with chitosan-CpG as combination adjuvants against Helicobacter pylori. , 2015, Biochemical and biophysical research communications.

[53]  A. Shukla,et al.  M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. , 2010, International journal of pharmaceutics.

[54]  S. Cryz.  Patient compliance in the use of Vivotif Berna(R) vaccine, typhoid vaccine, live oral Ty21a. , 1998, Journal of travel medicine.

[55]  F. Gao,et al.  Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus. , 2007, Vaccine.

[56]  M. Prato,et al.  Synthesis, structural characterization, and immunological properties of carbon nanotubes functionalized with peptides. , 2003, Journal of the American Chemical Society.

[57]  M. Mahdavi,et al.  Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model. , 2017, Journal of infection and public health.

[58]  I. Sjöholm,et al.  Starch microparticles as a vaccine adjuvant: only uptake in Peyer's patches decides the profile of the immune response. , 2006, Vaccine.

[59]  N. Restifo,et al.  DNA and RNA-based vaccines: principles, progress and prospects. , 1999, Vaccine.

[60]  S. Rautenschlein,et al.  Mucosal application of cationic poly(D,L-lactide-co-glycolide) microparticles as carriers of DNA vaccine and adjuvants to protect chickens against infectious bursal disease. , 2013, Vaccine.

[61]  A. Coombes,et al.  The potential for production of freeze-dried oral vaccines using alginate hydrogel microspheres as protein carriers , 2014 .

[62]  Seunghoon Han.  Clinical vaccine development , 2015, Clinical and experimental vaccine research.

[63]  Qiaojun He,et al.  Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells , 2016, Oncotarget.

[64]  A. Ray,et al.  Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination. , 2009, Journal of microencapsulation.

[65]  Fredrickson,et al.  Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores , 1998, Science.

[66]  S. Bertholet,et al.  New horizons in adjuvants for vaccine development. , 2009, Trends in immunology.

[67]  M. Hilleman.  Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. , 2000, Vaccine.

[68]  M. Roberfroid,et al.  Functional food science and gastrointestinal physiology and function , 1998, British Journal of Nutrition.

[69]  A. Andrianov,et al.  Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. , 1998, Vaccine.

[70]  M. Skwarczynski,et al.  Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus. , 2016, Nanomedicine.

[71]  O. Morozova,et al.  Comparative characteristics of the VP7 and VP4 antigenic epitopes of the rotaviruses circulating in Russia (Nizhny Novgorod) and the Rotarix and RotaTeq vaccines , 2015, Archives of Virology.

[72]  Bijay Singh,et al.  Combinatorial Approach of Antigen Delivery Using M Cell-Homing Peptide and Mucoadhesive Vehicle to Enhance the Efficacy of Oral Vaccine. , 2015, Molecular pharmaceutics.

[73]  Sanyog Jain,et al.  Divalent toxoids loaded stable chitosan-glucomannan nanoassemblies for efficient systemic, mucosal and cellular immunostimulatory response following oral administration. , 2015, International journal of pharmaceutics.

[74]  M. Marden,et al.  Artificial oxygen carrier based on polysaccharides-poly(alkylcyanoacrylates) nanoparticle templates. , 2010, Biomaterials.

[75]  Narendra Kumar Jain,et al.  Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. , 2006, Critical reviews in therapeutic drug carrier systems.

[76]  Qinfu Zhao,et al.  Investigation of 3D ordered macroporous carbon with different polymer coatings and their application as an oral vaccine carrier. , 2015, International journal of pharmaceutics.

[77]  P. Opanasopit,et al.  Methylated N-(4-N,N-dimethylaminocinnamyl) chitosan-coated electrospray OVA-loaded microparticles for oral vaccination. , 2013, International journal of pharmaceutics.

[78]  S. Davis,et al.  PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. , 1999, Vaccine.

[79]  T. Qin,et al.  CpG DNA assists the whole inactivated H9N2 influenza virus in crossing the intestinal epithelial barriers via transepithelial uptake of dendritic cell dendrites , 2014, Mucosal Immunology.

[80]  P. Pry.  The Delivery Systems , 2019, Israel's Nuclear Arsenal.

[81]  J. Nah,et al.  Targeted delivery of chitosan nanoparticles to Peyer's patch using M cell-homing peptide selected by phage display technique. , 2010, Biomaterials.

[82]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[83]  Haitao Jiang,et al.  Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties. , 2012, International journal of pharmaceutics.

[84]  S. Troy,et al.  Adjuvants and inactivated polio vaccine: a systematic review. , 2012, Vaccine.

[85]  A. Fooks,et al.  Induction of immunity using oral DNA vaccines expressing the measles virus nucleocapsid protein. , 2000, Developments in biologicals.

[86]  K. Fukuzaki,et al.  Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer1 , 2009, The Journal of Immunology.

[87]  T. Vermonden,et al.  The effect of lauryl capping group on protein release and degradation of poly(D,L-lactic-co-glycolic acid) particles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[88]  J. Gauldie,et al.  Immunization with adenovirus at the large intestinal mucosa as an effective vaccination strategy against sexually transmitted viral infection , 2008, Mucosal Immunology.

[89]  T. Delair,et al.  Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells. , 2010, Biomaterials.

[90]  Samir Mitragotri,et al.  Physical approaches to biomaterial design. , 2009, Nature materials.

[91]  M. Patarroyo,et al.  Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. , 2004, Vaccine.

[92]  I. Sjöholm,et al.  Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. , 2002, Vaccine.

[93]  M. Kapulu,et al.  Adjuvant potential of low dose all‐trans retinoic acid during oral typhoid vaccination in Zambian men , 2014, Clinical and experimental immunology.

[94]  D. Tambourgi,et al.  Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15. , 2010, Vaccine.

[95]  Alexander K Andrianov,et al.  Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy)phosphazene]. , 2006, Biomacromolecules.

[96]  T. Kosten,et al.  Vaccines against stimulants: cocaine and MA , 2014, British journal of clinical pharmacology.

[97]  R. Zhuo,et al.  PEI grafted hyperbranched polymers with polyglycerol as a core for gene delivery. , 2010, Colloids and surfaces. B, Biointerfaces.

[98]  M. van de Weert,et al.  Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[99]  Lei Zhang,et al.  Inositol based non-viral vectors for transgene expression in human cervical carcinoma and hepatoma cell lines. , 2014, Biomaterials.

[100]  K. Arimori,et al.  Modification of release rates of cyclosporin A from polyl(L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[101]  D. Tomalia.  Dendrimer research. , 1991, Science.

[102]  Qinfu Zhao,et al.  Investigation of 3-D ordered materials with a high adsorption capacity for BSA and their potential application as an oral vaccine adjuvant. , 2014, Journal of colloid and interface science.

[103]  C. D. Quadros,et al.  Brote de poliomielitis en Haití y la República Dominicana debido a un virus derivado de la vacuna antipoliomielítica oral , 2001 .

[104]  M. Levine,et al.  Safety and Immunogenicity of Single-Dose Live Oral Cholera Vaccine Strain CVD 103-HgR, Prepared from New Master and Working Cell Banks , 2013, Clinical and Vaccine Immunology.

[105]  M. Lebens,et al.  Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae. , 2016, Vaccine.

[106]  M. Jang,et al.  Oral Immunization with Helicobacter pylori‐Loaded Poly( d, l‐Lactide‐Co‐Glycolide) Nanoparticles , 1999, Helicobacter.

[107]  David J Brayden,et al.  Targeting polymerised liposome vaccine carriers to intestinal M cells. , 2001, Vaccine.

[108]  James Alexander,et al.  Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. , 2009, Vaccine.

[109]  A. Ray,et al.  Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination , 2009, Journal of microencapsulation.

[110]  J. Kwang,et al.  Recombinant Baculovirus Associated with Bilosomes as an Oral Vaccine Candidate against HEV71 Infection in Mice , 2013, PloS one.

[111]  R. K. Evans,et al.  Enhancement of DNA vaccine potency using conventional aluminum adjuvants. , 1999, Vaccine.

[112]  Hiraku Onishi,et al.  Preparation of double liposomes and their efficiency as an oral vaccine carrier. , 2006, Biological & pharmaceutical bulletin.

[113]  Kutty Selva Nandakumar,et al.  Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases , 2013, Journal of The Royal Society Interface.

[114]  H. Greenberg,et al.  Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles , 1998, Journal of Virology.

[115]  J. Wong,et al.  The potential of liposome–encapsulated ciprofloxacin as a tularemia therapy , 2014, Frontiers in Cellular and Infection Microbiology.

[116]  J. Nah,et al.  Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. , 2014, Biomaterials.

[117]  Bing Wang,et al.  Oral vaccination with a liposome‐encapsulated influenza DNA vaccine protects mice against respiratory challenge infection , 2014, Journal of medical virology.

[118]  M. Jaroniec,et al.  Ordered mesoporous silica SBA-15: a new effective adjuvant to induce antibody response. , 2006, Small.

[119]  A. Shukla,et al.  Bilosomes in the context of oral immunization: development, challenges and opportunities. , 2016, Drug discovery today.

[120]  J. Mcghee,et al.  Mucosal and systemic responses to an oral liposome-Streptococcus mutans carbohydrate vaccine in humans. , 1990, Regional immunology.

[121]  L. Babiuk,et al.  PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens , 2010, Journal of immune based therapies and vaccines.

[122]  H. Ch'ng,et al.  Evaluation of possible mechanism(s) of bioadhesion , 1998 .